(PFNX) |
0 (0%) 04-25 04:34 |
Open: | |
High: | |
Low: | |
Volume: | 0 |
Market Cap: | 0(M) |
PE Ratio: | 0 |
Exchange: | |
Industry: | |
Sector: |
Technical analysis | ||||
sell | buy |
Resistance 2: | 15.13 |
Resistance 1: | 12.95 |
Pivot price: | 12.73 |
Support 1: | 12.67 |
Support 2: | 12.50 |
52w High: | |
52w Low: |
EPS | -0.100 |
Book Value | 2.430 |
PEG Ratio | 0.00 |
Gross Profit | 1.325 |
Profit Margin (%) | -7.03 |
Operating Margin (%) | -7.53 |
Return on Assets (ttm) | -2.5 |
Return on Equity (ttm) | -4.3 |
Fri, 11 Dec 2020
Primecap Management Dissolves Pfenex Holding, Boosts Biogen - Yahoo Finance
Mon, 10 Aug 2020
Ligand to Acquire Pfenex Inc. - Business Wire
Mon, 13 May 2019
Pfenex: The First U.S. Forteo Biosim And A Host Of Other Biosims In Pipeline (NYSEMKT:PFNX-DEFUNCT-156623) - Seeking Alpha
Mon, 08 Aug 2016
Pfizer returns rights to Pfenex for Lucentis biosimilar - Fierce Biotech
Fri, 19 Jun 2015
Biosimilar of Novartis' eye drug Lucentis launched in India - FiercePharma
Wed, 30 Jul 2014
Sequenom Inc. Announces Closing Of Initial Public Offering - BioSpace
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |